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1.  INTRODUCTION 
 Memory is one of the most essential roles of the brain. Memory is vital for survival 
because it is the process by which organisms are able to record their experiences and use this 
information to adapt their responses to the environment. Loss of memory and cognitive 
impaired functions are the major features of Alzheimer’s disease (AD). Presence of 
acetylcholine within the neo cortex is sufficient to ameliorate learning deficits and restore 
memory. Decreased cholinergic firing in brain, rise in oxidative stress, hypercholesterolemia, 
and neuroinflammatory reactions have been demonstrated to play an etiological role in 
memory decline. The central cholinergic system is involved in cognitive functions and plays 
an important role in learning and memory for humans and animals
1
. 
Alzheimer’s disease (AD) is progressive irreversible neurodegenerative disorder that 
was first identified and written by Dr. Alois Alzheimer in early 1900s. It occurs gradually and 
results in cognitive impairment, unusual behaviour, personality changes, an ultimately death. 
It is the most common form of adult onset dementia. Presently, it is the 4
th
 leading cause of 
death in western countries, preceded only by heart disease, cancer and stroke. 
The world Alzheimer report 2015 led by king’s college London found that there are 
currently around 46.8 million people living with dementia around the world, with numbers 
projected to nearly double every 20 years, increasing to 74.7 million by 2030 and 131.5 
million by 2050.In India 4.1 million of people are living with dementia. There are an 
estimated 5.3 million Americans of all ages with Alzheimer’s disease. In 2015, an estimated 
7,00.000 Americans age ≥65 years will die with AD, and many of them will die from 
complications caused by AD
2
. 
The term “dementia” describes a loss of mental ability associated with gradual death 
of brain cells. The most common cause of dementia in the elderly is probably Alzheimer’s 
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disease (AD), a chronic, progressive disabling organic brain disorder characterized by 
disturbance of multiple cortical functions, including memory, judgment, orientation, 
comprehension, learning capacity and language
3
. 
 Amnesia is the general term for a condition in which memory (either stored memories 
or the process of committing something to memory) is disturbed or lost, to a greater extent 
than simple everyday forgetting or absent mindedness. 
Amnesia may result either from organic or neurological causes (damage to the brain 
through physical injury, neurological disease or the use of certain drugs), or from functional 
or psychogenic causes (psychological factors, such as mental disorder, post-traumatic stress 
or psychological defence mechanisms)
4
. 
CAUSES OF ALZHEIMER’S DISEASE4 
 It is a neurodegenerative disease, which means there is progressive brain cell death 
that happens over a course of time. The total brain size shrinks with Alzheimer’s – the tissue 
has progressively fewer nerve cells and connections. In Alzheimer’s disease, brain cells start 
to deteriorate. The body attempts to stop this process by producing a protein called amyloid. 
However amyloid deposits build up in the brain, leading to further deterioration. 
 These deposits of amyloid are referred to as “plaques” and cause the brain cells to 
shrivel up and form “tangles”, which in turn lead to changes in the brain structure and cause 
the brain cell to die.  
The formation of plaques and tangles also prevents the production of some important 
brain chemicals, called neurotransmitters. Over time the loss of brain cells cause the brain to 
shrink. 
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Figure: 1 
 
PATHOPHYSIOLOGY OF ALZHEIMER’S DISEASE6-8 
 The pathophysiology of Alzheimer’s disease is complex, involving many 
neurotransmitter systems and pathophysiologic processes. 
 Change in brain structure 
 Degenerative processes in Alzheimer’s disease 
 β amyloid hypothesis 
 The cholinergic hypothesis 
 The glutamatergic/ excitotoxicity hypothesis 
 The oxidative stress hypothesis 
 The chronic inflammation hypothesis 
3. Other neurotransmitter deficiencies 
4. Cholesterol 
 
INTRODUCTION 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 4 
 
1. Changes in brain structure 
    In this disease, brain atrophy and neuronal loss occur in a predictable pattern beginning 
with the entorhinal cortex and hippocampus, ultimately progressing throughout the brain. 
Figure: 2 
 
 
2. Degenerative processes in Alzheimer’s disease6-8 
   This disease is characterized by 3 neuropathologic hallmarks: 
 Plaques of β-amyloid protein 
 NFTs 
 Neuronal degeneration 
All of which occur during normal aging, but in disease occur in specific location in the brain. 
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β-amyloid plaques 
 These are thought to play the central role in AD pathogenesis, described as the 
“amyloid cascade”                         
Figure: 3 
 
Neuro Fibrillary Tangles 
   The β-amyloid hypothesis maintains that formation of β-amyloid plaques is the first 
step in AD pathology and genetic and histopathologic studies support this hypothesis. NFTs 
occur after   plaque formation.  
Figure: 4 
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The cholinergic hypothesis 
 This is supported by the drastic and widespread loss of cholinergic neurons in AD, the 
benefits with acetylcholinesterase inhibitors and the role of the nicotinic cholinergic receptor.
 
The glutamate/excitotoxicity hypothesis 
 It maintains that slow but steady activation of a glutamate receptor leads to cellular 
damage.
 
The oxidative stress hypothesis 
 It suggests that β- amyloid induces oxidative stress causing permanent damage to 
some neuronal macromolecules and creating reactive species, which further propagate 
neuronal toxicity. 
Figure: 5 
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The chronic inflammation hypothesis 
 This inflammation observed with Alzheimer’s disease is thought to be the result of all 
of these mechanisms causing cell damage and death. In Alzheimer’s disease, inflammatory 
cytokines respond to these processes and contribute to neuronal destruction because they 
appear to act uninhibited
6, 7
. 
Other neurotransmitters deficiencies 
 Serotonin and norepinephrine are also involved in Alzheimer’s disease pathology. 
Serotonin is an important factor in depression and anxiety, both of which are common in 
patients with Alzheimer’s disease. 
Cholesterol 
 This is also appears to have a role in Alzheimer’s disease progression, perhaps 
through a reduction in vascular risk factors, which are common in patients with Alzheimer’s 
disease 
Figure: 6
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STAGES OF ALZHEIMER’S DISEASE8-10 
STAGE ONE: FORGETFUL
 
Mild or early stages, lasts for 2 to 8 years. Person needs occasional reminders, lists and 
routine. 
 Short term memory loss. 
 Disorientation to time; spatial disorientation. 
 Aphasia, mild anomia, some circumlocution. 
 Mild apraxia. 
 Judgment errors. 
 Affect changes. 
 Absent-minded, difficulty concentrating. 
 Behavior or lifestyle changes. 
 Self-aware or unaware of deficits or changes. 
STAGE TWO: CONFUSION 
   Middle/Moderate stage, lasts for 3 to 6+ years. Person needs occasional assistance and 
supervision. 
 Short-term and remote memory loss. 
 Needs help with activities of daily living (bathing, toileting, etc.) 
 Emotional ups and downs. 
 Aphasia, paraphasia with semantic/phonemic errors. 
 Ideational and ideomotor apraxia. One or two steps skills. 
 Agnosia; less able to interpret sensory input (visual, touch, etc.) 
 Restless, listless, wandering or slow moving, hard to motivate (abulia). 
 Clumsy movement, decreased muscle control and some ataxia. 
INTRODUCTION 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 9 
 
 
STAGE THREE: DEMENTIA 
   Severe or end stage lasts for 1 to 4 years. Person needs constant supervision and assistance. 
Respite essential to primary caregiver. 
 Decreased communication skills, difficulty talking or understanding. 
 Apraxia, one step skills. 
 Perseveration. 
 Minimal motor control. 
 Forgets social graces, decreased gating, and spontaneous outbursts. 
 Behavioral problems, such as wandering, unwilling to bathe or dress. 
 Incontinent. 
 Bedridden. 
Identified risk factors for developing the condition include: 
 Increasing age 
 History of the head injury 
 Down’s syndrome 
 Risk factors for blood vessels disease such as smoking 
 Family history of Alzheimer’s disease 
 Obesity 
 High blood pressure 
 High cholesterol 
 Insulin resistance. 
 Genetic factor 
 Environmental factor 
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SIGNS AND SYMPTOMS OF ALZHEIMER’S DISEASE 13, 62, 64 
Memory loss  
Forgetting recently learned information is one of the most common early signs of 
dementia. 
Difficulty performing familiar tasks 
People with dementia often find it hard to plan or complete everyday tasks. 
Problems with language 
People with this disease often forget simple words or substitute unusual    words, 
making their speech or writing hard to understand. 
Disorientation to time and place  
People with this disease can become lost their neighbor’s, forget where they are and 
how they got there, and not know how to get back home. 
Poor or decreased judgment  
Those with Alzheimer’s disease may dress inappropriately, wearing several layers on 
a warm day or little clothing in the winter. They may show poor judgment. 
Problems with abstract thinking  
Someone with Alzheimer’s disease may have unusual difficulty performing complex 
mental tasks, like forgetting what numbers are and how they should be used. 
Misplacing things  
A person with Alzheimer’s disease may put things in unusual places, an iron in the 
washing machine or a watch in the freezer. 
 
 
INTRODUCTION 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 11 
 
Change in mood or behavior  
Someone with Alzheimer’s disease may show rapid mood swings- from calm to tears 
to anger- for no apparent reason. 
 
Change in personality  
The personalities of people with dementia can change dramatically. They may 
become extremely confused, fearful or dependent on a family member. 
Loss of initiative  
A person with Alzheimer’s disease may become very passive, sitting in front of the 
television for hours, sleeping more than usual or not wanting to do usual activities 
TREATMENT OF ALZHEIMER’S DISEASE14-19 
 
Treatment of Alzheimer’s disease there is no cure for Alzheimer’s disease and drug 
therapy for the disease is still in its infancy. 
 
 Acetylcholinesterase inhibitors help improve memory function and attention in 
Alzheimer’s disease patients by interfering with the breakdown of acetylcholine, thereby 
increasing the levels of the neurotransmitter at the synapse. There are currently three FDA-
approved cholinesterase inhibitors: rivastigmine and galantamine(for mild to moderate 
Alzheimer’s disease), and donepezil (for all stages of Alzheimer’s disease)15. 
 Memantineis another FDA-approved medication for use in moderate to severe 
Alzheimer’s disease but belongs to a different class of drugs known as NMDA (glutamate) 
receptor antagonists. 
 Antioxidants such as vitamin-E (α tocopherol) monoamino oxidase inhibitor 
(selegiline), phenolics (curcumin), tannins (gallic acid) and polyphenolics (ferulic acid) 
reduce the free radical formation and prevent the cognitive syndromes. 
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 Several vaccines are under development to reduce the cognitive symptoms due to 
Alzheimer's disease. 
The discovery of novel Alzheimer’s diseasetreatments and has been used in the past 
for other neurodegenerative disorders (e.g., anti-viral drug amantadine for use in Parkinson’s 
disease)
15,16
. 
 Nootropic agents such as aniracetam, piracetam,and pramiracetam and choline 
esterase inhibitors like donepezil, rivastigmine are being primarily used to improve memory, 
mood and behaviour. 
 According to the WHO more than 80% of the world’s population relies on traditional 
herbal medicine for their primary healthcare. In recent time there has been a marked shift 
towards herbal cures because of the pronounced cumulative and irreversible reactions of 
modern drugs. 
As we know that India, with its mega biodiversity and knowledge-rich ancient 
traditional system of medicine viz Ayurveda, Siddha, Unani and  local health 
traditions,provides a strong base for the utilization of a large number of plants in general 
healthcare of the people
5
. 
 Desmodium gangeticumand reported that the alkaloids indole -3-alkylamines and β 
carbolines has biological activities like anticholinesterase, smooth muscle stimulant and CNS 
stimulant response. And also studied the chemical composition of the roots and reported three 
pterocarpeniods, gangetin, gangetininand desmodin respectively
5
. 
Gangetin, a pterocarpan, shows anti-fertility activity by affecting alkaline phosphatase 
activity in uterine fluids. It is reported to possess antiulcer, antioxidant, cardio tonic, anti-
inflammatory, anti-nociceptive activities and useful in neurological disorders. Therefore, it is 
worthwhile to explore the utility of traditional medicines for the treatment of various 
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cognitive disorders. Gangetin,gangetininand desmodinare the major chemical constituents 
present in the root of Desmodium gangeticum
5
. 
 About 38 different species of Desmodium have been reported in India of which 
Desmodium gangeticumand Desmodium adscendens are used ethno medically all over the 
world.Among which Desmodium gangeticum is used in the Indian system of medicine; 
particularly in the Ayurveda is an important and well explored species of genus Desmodium. 
Desmodium gangeticum contains majorly alkaloids, flavonoids and pterocarpinoids. 
The Ayurvedic herbs Brahmi, Ashwagandha, Curcumin, Arcoruscalamus, 
Shankhpushpi, Zingiber, etc help to improve Alzheimer’s situation17, 18. 
 Ultimately, the most successful model of treatment for Alzheimer’s disease will likely 
include early detection and control of physical factors (diabetes, hypertension, 
hyperlipidemia), followed by application of multifaceted, disease-modifying interventions to 
prevent the early and continued loss of neurons and to reduce the toxins that result in further 
cell deterioration
15
. 
This plant is one among the Dashamoola (roots) of Ayurveda and is an important 
ingredient of many famous Ayurvedic drugs like Dashamoolarishta(anemia, haemorrhoids, 
liverdisease), Chyavanaprasha(it act against the ageing process, anti-oxidant), 
Dhanwantharam Kuzhambu( useful in treatment of neurological conditions such as 
Neuritis, Neuralgia), Rasnadhi decoction(Rheumatoid arthritis), Agusthya 
Rasayanam(Respiratory disease), Sukumbaragritham(used an inflamations), 
DasamulaKatuthiayadikashayam(anti-inflammatory), Dasamulathailam(ascites), 
Danvantrathailam(headache, Neuro muscular conditions), Mahamasahthailam(Widely 
used for many neurological conditions), Anuthailam(improve memory and functions of four 
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sense organs and also nervous disorders), Vidaryadigritham(used in treatment for myalgia) 
and Brahma Rasayan(it helps to fight tiredness, fatigue, stress and aging)
5
. 
 This study was undertaken to evaluate the potential benefits of Desmodium 
gangeticum (fabaceae) root using mice as animal model for the treatment of Alzheimer’s 
disease. 
 
AIM AND OBJECTIVE 
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2. AIM AND OBJECTIVE 
 Desmodium gangeticum has been reported to possess antioxidant activity and anti-
inflammatory activities are known to be associated with Nootropic activity.  
 In this plant, the aerial part of Desmodium gangeticum has been shown to possess 
anti-amnesic activity. No work has so far been carried out on the roots of Desmodium 
gangeticum. 
Hence, the aim and objective of the present study is to, 
 To extract the root of Desmodium gangeticum by hot continuous extraction 
using Soxhlet apparatus using various solvents n-hexane, ethyl acetate and 
ethanol.  
 To evaluate the neurotransmitter (acetylcholinesterase and serotonin) 
estimation of ethyl acetate and ethanol root extracts of Desmodium 
gangeticum by ex vivo method. 
 To evaluate the memory activity of ethyl acetate and ethanol root extracts of 
Desmodium gangeticum by in vivo (Morris water maze and Y maze) method. 
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3. REVIEW OF LITERATURE 
 Vaghela et al.(2013) was demonstrated the Desmodium gangeticum is quite 
promising as a multipurpose medicinal agent. So further clinical trials should be 
performed to prove its efficacy
20
. 
 
 T. ShriVijayaKirubha et al. (2011) was demonstrated the Desmodium gangeticum 
serves as one of the main ingredient of famous Ayurvedic preparations. Thus, the 
utility of Desmodium gangeticum as a medical plant has increased many folds over a 
period of time
21
. 
 
 Prasharet al.(2014) was demonstrated that protocatechuic acid has potential 
therapeutic effects on improving the anti-amnesic activity in rats through inhibiting 
lipid peroxidation and decreasing acetylcholinesterase (AChE) in brain
23
. 
 
 Yi-fan Han et al.(2012) was concluded that B3C and B7C might provide greater 
therapeutic efficacy for the treatment of AD by concurrently acting on multiple 
targets’s, including inhibiting AChE, blocking NMDA receptor and antagonizing 
GABAA receptor
24
. 
 
 Kulkarni et al.(2011) was investigated the effect of Cissampelos pariera on learning 
and memory in scopolamine induced mice. Based on results of experiments, found 
that CPE had remarkable cognitive enhancing activity
25
. 
 
 Mehrdad jahanshahiet al. (2011) was concluded that scopolamine, as a non-
selective muscarinic receptor antagonist, can significantly shorten the latency 
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compared to the saline control group in test day. Also it can reduce the number of 
neurons in sub-regions of hippocampal formation
26
. 
 
 Ajay J Parikh et al.(2013) was concluded guggul extract is a hypolipidemic agent 
and can be exploited as antialzheimer’s agent and also shows significant synergistic 
effect when co-administered with piracetam
27
. 
 
Anti-inflammatory activity 
 R. Govindarajan et al.(2007) has been studied the flavonoid and alkaloid fractions of 
Desmodium gangeticum were evaluated for anti-inflammatory activities in 
carrageenan-induced inflamed rats with the aim of studying the promising fraction for 
inhibitory action on ferrous sulphate induced lipid peroxidation, superoxide dismutase 
(SOD), catalase(CAT), glutathione peroxidase (GPX) and total reduced glutathione in 
liver and spleen homogenates of inflamed rats
22
. 
 
 AnshuRathiet al. (2004) has been studied the water decoction of root and aerial parts 
of Desmodium gangeticum was examined for anti-inflammatory activity in 
experimental animals. There was a significant increase in analgesio-meter-induced 
force equivalent to6.56–67.66% protection and 22.18–73.83% protection in acetic 
acid-induced writhing
20
. 
 
 D. Ghosh and A. Anandakumar (1983) were reported the Gangetin isolated from 
the hexane extract of the root of the plant Desmodium gangeticum. The compound 
showed significant anti-inflammatory activity in the exudative and the proliferative 
phases of inflammation in the doses of 50 and 100mg/kg orally in albino rats
69
. 
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 ShivaniGhildiya et al.(2013) was studied that Laghupanchamula denotes 
combinations of roots of five herbs. However, in Ayurvedic classics besides four 
common herbs viz. Kantakari, Brihati, Shaliparni and Prinshniparni, the fifth one is 
either Gokshura (Laghupanchamula with Gokshura LPG) or Eranda 
(Laghupanchamula with Eranda LPE), and both formulations have been documented 
to have shothahara (anti-inflammatory) action. Compare the anti-inflammatory 
activity of 50% ethanolic extract of LPG and LPE were studied in in rats and in mice. 
LPG and LPE significantly reduced acute and sub-acute inflammation and showed 
effective and similar anti-inflammatory activity
70
. 
Anti-nociceptive activity 68 
 AnshuRathi et al.(2004) was studied the water decoction of root and aerial parts of 
Desmodium gangeticum was examined for anti-nociceptive activity in experimental 
animals. The result establishes the traditional use of water decoction of Desmodium 
gangeticum codified in Indian System of Medicine. 
Analgesic activities20 
 D. Ghosh and A. Anandakumar(1983) were reported the Gangetin isolated from the 
hexane extract of the root of the plant Desmodium gangeticum. The compound 
showed significant analgesic activity in albino rats. 
 
Anti-amnesic activities19 
 Joshi Hanumanthachar and Parle Milind (2007) has been studied the effectiveness 
of aqueous extract of Desmodium gangeticum (whole plant) in attenuating 
scopolamine-induced amnesia in mice. It increased mice brain acetylcholine content 
and decreased acetyl cholinesterase activity in a similar manner to the standard 
cerebro-protective drug piracetam. Hence, aqueous extract of D. gangeticum can be 
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used to delay the onset and reduce the severity of the symptoms of dementia and 
Alzheimer’s disease. . 
 
Anti-oxidant activity 
 R. Govindarajan et al. (2006) has been studied the total alcoholic extract of 
Desmodium gangeticum, which exhibited significant anti-inflammatory activity and 
was evaluated for the possible mode of action by studying its antioxidant potential in 
adjuvant-induced arthritic rats
28
. 
 Prakash Veeru1 et al. (2009) was studied some medicinal plant extracts for       anti-
oxidant activity and after ending of study he was consulted the methanolic crude 
extracts of Desmodium gangeticum found to be the strongest antioxidant, followed in 
descending order by Amaranthuscaudatus, Solanumnigrum, Piper longum, Eclipta 
alba and Ocimum sanctum
20
. 
 Gino A Kurian et al. (2009) was reported the effect of aqueous extract of 
Desmodium gangeticum root in different antioxidant models and experimentally 
induced ischemic reperfusion in an isolated rat heart. The rats were divided into three 
groups namely control, reperfusion control and drug treated. The above results 
suggest that the aqueous extract of DG root exhibit potential free radical scavenging 
effect that can reduce the oxidative stress exhibited by IRI
29
. 
 Jen-Chieh Tsai et al. (2009) was studied antioxidant activities and phenolic 
components of the crude extracts of 10 Desmodium species from Taiwan. In this 
study, DPPH free radical scavenging activity, ABTS radical monocation scavenging 
activity, ferric-reducing antioxidant power (FRAP) and reducing power of the 10 
Desmodium species were evaluated for their antioxidant activities
20
. 
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Anti-pyretic activity 
 Zhan-Zhou Zhu et al. (2006) was studied the petroleum ether fraction (PEF) from 
the ethanol extract of Desmodium gangeticum, which finding significantly antipyretic 
activities in mice
20
. 
 
            Anti-diabetic activity20 
 Govindarajan R. et al. (2007) was studied the insulin secretion and anti-diabetic 
activity of Desmodium gangeticum. Treatment of diabetic rats with aerial parts of D. 
gangeticum extract (DG, 100 and 250mg/kg body weight) for 3 weeks showed a 
significant reduction in blood glucose. D. gangeticum extract caused a significant 
increase in insulin secretion from MIN6 cells grown as monolayers and as pseu- 
doislets, indicating that the antidiabetic activity may be as a result of increased insulin 
secretion. It also had a role on the lipid profile of the rats by causing reductions in 
cholesterol and triglycerides and increasing the HDL significantly. 
 
             Cardiovascular activity 
 G. A. Kurian et al.(2008)  was evaluated the effect of a methanol extract of 
Desmodium gangeticum (L) DC (Fabaceae) (DG) on lipid per-oxidation and 
antioxidants in mitochondria and tissue homogenates of normal, ischemic and 
ischemia-reperfused rats. The results of their study showed that DG possesses the 
ability to scavenge the free radicals generated during ischemia and ischemia 
reperfusion and thereby preserves the mitochondrial respiratory enzymes that 
eventually lead to cardio protection
30
. 
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 G. A. Kurian and Jose Paddikkala (2012) was studied mimetic action of herbal 
extract Desmodium gangeticum (DG) roots on ischemia reperfusion injury. The 
results with physiological parameters like left ventricular developed pressure, end 
diastolic pressure and working index of isolated rat heart showed significant recovery 
in DG root extract administrated rat heart. So they concluded DG methanol root 
extract provides myocardial protection towards IRI by stimulating muscarinic 
receptors
29
. 
 
 M. M. Shabi and L. Upadhyaya(2012) was studied the effect of Desmodium 
gangeticum on lysosomal hydrolases, phosphatases and electrolytes in mechanically 
induced myocardial ischemic injury in rats. They concluded that alteration in this 
enzyme activities may lead change in the electrolytes such as sodium, potassium and 
calcium content in the heart during ischemic reperfusion injury
20
. 
 
 Sankar et al. (2013) was studied Cardiac hypertrophy occurs in response to increased 
workload, such as hypertension or valvular heart disease. Oxidative stress has been 
implicated in cardiac hypertrophy and in its transition to heart failure. The methanolic 
root extract was analyzed for total phenolic content and tested for antioxidant 
potential. The results demonstrated potent free radical scavenging activity of DG. Cell 
line studies showed significant increase in ROS generation, and permeability 
transition pore opening in ISO-treated cells. This study is the first documentation of 
the modulatory effect of DG on cardiac hypertrophy
20
. 
         Anti-ulcer activity 
 Dharmani P et al. (2005) was reported anti-ulcerogenic property of ethanolic extract 
of Desmodium gangeticum against cold restraint (CRU, 2 hr cold restraint stress), 
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aspirin (ASP, 150 mg/kg orally), alcohol (AL, absolute alcohol 1 ml/200gm) and 
pyloric ligation (PL, 4 hr pylorus ligation) induced gastric ulcer models in Sprague 
Dawley rats and histamine (HST, 0.25 mg/kg) induced duodenal ulcer in guinea pigs. 
Treatment with DG showed increase in mucin secretion by 56.17%, whereas OMZ 
showed 12.45% increase. Anti-ulcer effect of DG may be due to its cytoprotective 
effect along with antisecretory activity and could act as a potent therapeutic agent 
against peptic ulcer disease
33
. 
 
 Ayyavu Mahesh et al. (2005) has been studied the ethanolic root extract of 
Desmodium gangeticum in various acute and chronic ulcer mouse models. Oral 
administration of root extract, significantly decrease the ulcer index and lesion 
number in a dose dependent manner against ethanol induced acute gastric ulcer in 
mice. In gastric ulcerated animal that received high dose of 150mg/kg, the mucosa 
showed no ulceration with slight focal congestion and the glands appeared normal. 
The highest dose (150mg/kg) of the extract provoked a marked increase in protein and 
glutathione levels, when compared to control. Our results indicate that the DG possess 
gastroprotective activity and increasing regeneration of damaged gastric mucosa and 
thus safe for human use
20
. 
            CNS activity 
Alzheimer's disease34 
 M Obulesu and D. MuralidharaRao (2011) were studied the extracts of plants and 
their effect on the amelioration of AD symptoms has been extensively. The 
mechanisms like acetylcholinesterase (AChE) inhibition, modification of 
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monoamines, antiamyloid aggregation effect and antioxidant activity which are 
actively entailed in the process of amelioration of AD symptoms. 
 
 .Jabbar S et al. (2001) was studied aqueous extract of Desmodium gangeticum and 
showed severe anti-writhing activity in the acetic acid-induced abdominal writhing 
assay. It exhibited moderate central nervous system depressant activity in the 
spontaneous motoractivity,  hole cross and open field tests and hole board tests. The 
effect of this extract on locomotion was compared with some standard CNS drugs.  
 
     Antibacterial activity20 
 Krishnasamy Karthikeyan et al. (2001) antibacterial activity of D. gangeticum was 
tested with various solvents viz., methanol, ethanol, chloroform and aqueous extract 
against various bacterial pathogens such as klebsiellapneumoniae, escherichia coli, 
salmonella typhi, streptococcus mutants and pseudomonas aeruginosa. Antibiotic 
sensitivity assay was performed with amoxicillin, kanamycin, tetracycline, 
ciprofloxacin and penicillin. The result of the selected several extract, the methanolic 
extract showed maximum zone of inhibition against S. mutants and minimum zone of 
inhibition was observed with aqueous extract against P. aeruginosa. In addition the 
antibiotic sensitivity was observed with kanamycin, tetracycline, and ciprofloxacin 
against all bacteria’s. The methonalic extract of D. gangeticum be able to use as 
potential antibacterial source for various infective pathogens. 
 
 
 
REVIEW OF LITERATURE 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 24 
 
    Wound Healing Activity 
 V. Jain, V. Prasad and R.S. Pandey (2006) were evaluated the aqueous extract of 
Desmodium gangeticum for its wound healing potential on different experimental 
models of wounds in rats. The aqueous extract of aerial part of DG, in powdered form 
was incorporated in ointment (10% w/w dried powder in simple ointment base) and 
was evaluated for wound healing potential in an excision, incision and dead space 
wound model in rats. The DG ointment showed significant responses in all three-
wound types tested when compared with the control group. The effect produced by 
the DG ointment, in terms of wound contracting ability, wound closure time, tensile 
strength of the wound, regeneration of tissues at wound site were comparable to those 
of a standard drug povidone iodine ointment
20
. 
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PLANT PROFILE
 
BOTANICAL NAME : Desmodium gangeticum 
FAMILY   : Fabaceae 
SYNONYM   :  Prisniparni,Prthkparni, Chitraparnyahi, Kalasi,  
    Dhavaniguha,Simhapucchi,  
    ParnyapiKrestuvinna. 
 
REGIONAL NAME 
20, 21 
Sanskrit       : Shalparni 
Tamil             :          Pulladi, Orilai 
 Telugu        :          Gitanaram, Kolakuporna 
Bengal          :          Salpani, Shalpani, Chhalani. 
English         :          Flax weed, Flix weed. 
Gujarati           :          Salvan,Shalvan,Sameravo,Pandadiyo. 
Hindi                       :          Shalpan,Saivan,Sarivan,Gauri,Sar,Salpani,Dinth. 
Kannada     :          Kadanga,Maru,Nabiyalabune,Nariyalavona,Bhui,Shevara. 
Konkani         :          Salvan 
 Malayalam    :          Orila,Pullati. 
 Marathi          :          Salvan,Ranbhal. 
Mundari          :          Oterai 
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TAXONOMIC CLASSIFICATION 
Kingdom              Plantae          - Plants 
Subkingdom      Tracheobionta            -   Vascular plants 
Superdivision    Spermatophyta           -   Seed plants 
Division             Magnoliophyta       -   Flowering plants 
Class                  Mangnoliopsida     -   Dicotyledons 
Subclass             Rosidae 
Order                   Fabales 
Family                 Fabaceae   - pea family 
Genus – Desmodium  Desv.  - ticktrefoil 
Species - Desmodium gangeticum (L.) DC. 
Part used   :  Roots 
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Figure: 8 
 
Figure: 9 
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HABITAT
20, 21
 
 The plant of Desmodium gangeticum is bitter, sweet, thermogenic,  nervetonic, 
febrifuge, digestive, anticatarrhal, antiemetic, aphrodisiac, demulcent, anthelmentic, 
cardictonic, anti-inflammatory, diuretic, hemostatic, rejuvenating and useful in 
neuromuscular and ophthalmic disorders, loss  of appetite, flatulence, diarrhoea, dysentery, 
piles, helminthiasis
21
. 
 The root of Desmodium gangeticum is one of the constituent of famous Ayurvedic 
preparation Dasmoola kvatha which is antipyretic and bitter tonic. It is reported to be 
beneficial in treatment of typhoid fever, biliousness and also diuretic and aphrodisiac. 
DISTRIBUTION 
 Common Species on lower Hills and Plains throughout India ascending to 1500m in 
the Himalayas. It is frequently found in outer Himalaya, Punjab, Tirunelveli, Kerala in forest 
and west lend of Bihar and Orissa, Palghat in Madhya Pradesh in open and wasteland forests 
of Rajasthan forest of Ganjam to Godavari, Ghats from South Canara to Travancore
21
. 
DESCRIPTION 
 Desmodium gangeticum which is commonly known as 
Saivan(Guajarati),Shalpan(Hindi) and Flax weed (English).It is a stout herb or under 
shrub, up to 1m.high, 
 Stem is angled, more or less hairy. 
 Leaves are 1-fololate,stipules is scarious, up to 8mm. long. 
 Leaflets-membranous,7-15*3-7cm,ovate – oblong or broadly ovate, acute or 
acuminate, rounded at the base. 
PLANT PROFILE 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 29 
 
 Flowers is in large terminal and axillary racemes, usually in small fascicles on a 
slender rachis; bracts subulate, up to 4mm, calyx-2mm long,hairy, 
 Corolla 4-5mm.long. purple, violet, blue, lilac, or white, these colours appearing at 
the same time on the same plant 
 Pods are slightly falcate, up to 18mm.long; joints 6-8, longer then broad, slightly 
hairy with minute hooked hairs
20,21
. 
CHEMICAL CONSTITUENTS
 
PLANT 
 N,N-dimethyitryptamine, 5-methoxy-N,N-dimethyltryptamine,  and their    Nb-
oxides, Nbmethyltetrahydroharman, 6-methoxy-2-methyl-β-carboliniumderivative, 
Nbmethailtetrahydroharman, hypaphorine, hordenine, caudicine, N-methyltyramine,  β 
phenylethylamine. 
ROOT 
 Three pterocarpenoides, gangetinin, gangetin and desmodin are the major chemical 
constituents of the roots. 
ETHANOMEDICAL USE 
 The plant of Desmodium gangeticum is bitter, sweet, thermo genic, nervine tonic, 
aphrodisiac, demulcent, anthelmintic, cardiac tonic, febrifuge, anti-inflammatory, diuretic, 
hemostatic, rejuvenating, and useful in neuromuscular and ophthalmic disorders, loss of 
appetite, flatulence, diarrhea, dysentery, nausea, piles, helminthiasis.It is used in angina pain, 
cardiac disorders, tuberculosis, cough, seminal weakness, urinary disorders, fever, debility 
and gout.  
The root of Desmodium gangeticum is one of the constituent of famous Ayurvedic 
preparation Dasmoola kvatha which is antipyretic and bitter tonic.It isreported to be 
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beneficial in treatment of typhoid fever, biliousness and also diuretic and aphrodisiac. The 
root is nervine tonic, diuretic, cardio tonic, and expectorant. The root decoction is used for 
the treatment of heart diseases, especially in angina pectoris and myocardial infarction. It 
strengthens heart muscles and reduces cholesterol. Roots are chewed daily for the cure of 
typhoid and pneumoni
20-21
. 
 The present study was undertaken to assess the memory enhancing potential of 
Desmodium gangeticum root extract in mice. 
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4. PLAN OF WORK 
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5. MATERIALS AND METHODS 
 5.1COLLECTION AND IDENTIFICATION OF PLANT MATERIAL 
 The roots of Desmodium gangeticum were collected from Institute of Siddha College, 
Tirunelveli  District, Tamil Nadu (India), in the month of November 2015.The plant material was 
identified and authenticated by Prof. V. Chelladurai, Research officer- Botany (Scientist-c) 
(Retd), Central Council for Research in Ayurveda& Siddha, Govt. of India 
5.2 PREPARATION OF VARIOUS EXTRACTS OF ROOTS OF Desmodium gangeticum 
 Roots of D.gangeticum were washed with distilled water to remove the dirt and soil and 
shade dried. The dried material were powdered and passed through a 10-mesh sieve.  About 50g 
of air dried powdered plant materials from the roots were transferred into thimble for packing 
and successing extracted using Soxhlet apparatus by hot continuous percolation method using 
solvents in the order n-Hexane followed by ethyl acetate and finally ethanol. 
 A piece of porcelain was added into the round bottom flask to avoid bumping effect. The 
extracts were filtered using whatmann filter paper No.40 and the solvent were recovered from 
the extracts under reduced pressure using rotary evaporator. 
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Table1. The percentage yield from the plant Desmodium gangeticum using different 
solvents 
 
 
 
 
 
 
 
5.3 MEMORY ENHANCING ACTIVITY 
 5.3.1 Acute toxicity study 
 Acute toxicity studies have been already done in previous studies and it was found to be 
safe up to 2000mg/kg.  
 The selection of Desmodium gangeticum dose was based on initial pilot study, whereas 
scopolamine
19
 and piracetam
23
 dose selection was based on previous literatures. The memory 
enhancing activity was investigated on various extracts of DG in Swiss albino mice fed with 
commercial pellet diet. 
5.3.2 EXPERIMENTAL DESIGN 
 The Institutional Animal Ethical Committee clearance were obtained vide reference 
09/243/CPCSEA dated for the study of memory enhancing activity in ethyl acetate and ethanol 
extracts of the roots of Desmodium gangeticum. 
 
Extract 
Weight of plant 
material used for 
extraction 
 
Yield (gm) 
 
PercentageYield(%) 
n-hexane 50gm 2.0 4 
Ethyl acetate 50gm 5.7 11.4 
Ethanol 50gm 8.3 16.6 
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Albino Mice (25-30gm) were procured from Animal House, Madras Medical College, 
Chennai, Tamil Nadu, India. They were acclimatized for laboratory condition for 7 days and 
randomly divided into five groups each having six animals. The animals were housed under 
standard laboratory conditions and maintained under a 12-h light- dark cycle and had free access 
to drinking water and diet for one week. All the protocols in this study were approved by the 
ethics committee of madras medical college. 
 For the pharmacological tests, the obtained extract was suspended in double distilled 
water containing carboxy methylcellulose (1%w/v CMC) in doses of ethyl acetate and ethanol 
extract 200mg/kg p.o. The doses were fixed based on earlier studies on the ethyl acetate and 
ethanol extract of Desmodium gangeticum roots extract were administered at up to end of the 
observation period. 
The Desmodium gangeticum root extract caused no abnormality or death during the 
course of treatment. 
5.2.3DRUG AND CHEMICALS 
Scopolamine was purchased from Sigma. Piracetam was purchased from local medical 
shop. 
5.3.4GROUPING OF ANIMALS
27 
 Total 30 animals (Swiss albino mice) were randomly divided into five different groups, 
each group containing 6 mice and treated for 18 days as follows; Scopolamine(0.4mg/kg)was 
administered at last three days. 
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Table: 2 
S.No Group Name of drug Dose No of 
animals 
Duration of 
dosage 
1 Group 1 Control NIL 6 18days 
2 Group 2 Scopolamine 0.4mg/kg 6 Last 3days 
3 Group 3 Piracetam+ Scopolamine  200mg/kg 6 18days 
4 Group 4 DG ethyl acetate 
extract+Scopolamine 
200mg/kg 6 18days 
5 Group 5 DG ethanol extract + 
Scopolamine 
200mg/kg 6 18days 
 
Group 1 
 It represented the control group.Vehicle was administered orally for eighteen successive 
days. 
Group 2 
 CMC was administered orally for fifteen successive days followed by Scopolamine 
(0.4mg/kg i.p) after 45 min of administration daily from 16
th
 day to 18
th
 day. 
Group 3 
  Piracetam injection was administered i.p for fifteen successive days followed by 
Scopolamine (0.4mg/kg i.p) after 45 min of administration daily from 16
th
 day to 18
th
 day. 
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Group 4 
 DG ethyl acetate extract was administered orally for fifteen successive days followed by 
Scopolamine (0.4mg/kg i.p) after 45 min of administration daily from 16
th
 day to 18
th
 day. 
Group 5 
 DG ethanol extract was administered orally for fifteen successive days followed by 
Scopolamine (0.4mg/kg i.p) after 45 min of administration daily from 16
th
 day to 18
th
 day. 
5.3.5 EXPERIMENTAL PROCEDURE 
Induction of Amnesia 
Amnesia mainly induced by using Scopolamine into the mice. Scopolamine, also known 
as L-Duboisine, and  Hyoscine, is an alkaloid drug with muscarinic antagonist effects. It is 
among the secondary metabolites of plants from Solanaceae (nightshade) family of plants. 
 Scopolamine exerts its effects by acting as a competitive antagonist at muscarinic 
acetylcholine receptors, specifically M1 receptors. Scopolamine is used as a standard/reference 
drug for inducing amnesia in man and Animals. The effects are generally interpreted as a 
cholinergic deficit and related to the hypothesis that acetylcholine is involved in memory 
functions. Scopolamine, besides influencing learning and memory, affects various types of 
behaviour (e.g., loco motor activity, anxiety, attention). 
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5.3.6 EXTEROCEPTIVE BEHAVIORAL MODELS 
 Morris water maze 
 Y-maze task 
5.3.7 NEUROTRANSMITTER ESTIMATIONS 
 Acetylcholinesterase 
 Serotonin  
5.3.6 MORRIS WATER MAZE
24,39 
 The procedure used was a modification (Han et al., 2009) method described by Morris 
(1984).  
Mice (25-30g) were trained to find a submerged platform (6.5cmdiameter1cm below 
surface) in a circular pool (diameter60cm; height30cm) filled with turbidity water 
(depth19.5cm; 25±1
◦
C). 
 External visual cues were placed around the pool to facilitate navigation of the animals. 
 The platform was fixed at SW (southwest) direction. Start positions alternated between 
NE (northeast), SE (southeast), and NW (northwest) direction in a pseudo-random fashion.  
Each mouse was placed in the water facing the wall of the pool and allowed to swim for 
60s to reach the platform.  
 Finding the platform was defined as being able to stay on it for at least 2s; mice that 
crossed the platform without stopping (jumping immediately back into the water) were left to 
swim until the termination of the trail.  
MATERIALS AND METHODS 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 38 
 
If mouse failed to find the platform in the allotted time, the mouse was manually placed 
onto the platform manually and assigned as a latency of 60s. 
 All mice were allowed to rest there for 5mts and then performed the next trial 
immediately. After the last trail, mice were dried with a cloth and then returned to their home 
cage. 
 Mice performed four consecutive trials per day over a 4-day training period. The time to 
reach the target (escape latency) for each mouse was recorded manually. On the last day (day-5) 
a probe trail was adopted. 
Each mouse started at NE and had to swim freely for 60 s. memory retention was 
measured by quantifying the time to reach in the target platform.  
5.3.6 SPONTANEOUS ALTERATION BEHAVIOR IN THE Y-MAZE TEST
41-43
 
 We examined continuous spontaneous alternation behaviour using the Y- maze 
apparatus. The Y-maze apparatus was made of black plastic with three arms (36cm×7cm×13cm) 
extending from a central platform at 120
0
. 
 Each animal was placed at the end of one arm and allowed to move freely through the Y 
maze during a session lasting for 8min. Arm entry was defined as the entry of 4 paws into one 
arm.The sequence of arm entries was recorded visually. Alternation was defined as multiple 
entries into the 3 arm (A,B or C) on overlapping triplet sets.  
The percentage of spontaneous alternation was calculated as the ratio of the actual-to-
possible alternations (defined as the total number of arm entries minus 2), multiplied by 100: as 
shown in the following equation: 
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Alternation (%) = [(number of alternation)/(total arm entries-2)] ×100 
Figure: 10 
 
5.3.7NEUROTRANSMITTER ESTIMATION PROCEDURE
42 
(i) Estimation of Acetylcholinesterase (AChE) Ellman’s method  
 Acetylcholinesterase (AChE) is an enzyme participating in cholinergic 
neurotransmission. It breaks down acetylcholine which terminates the neurotransmission 
process. The most common assay is based on Ellman’s method using an alternative substrate 
acetylthiocholine and 5, 5’-dithio-bis-2-nitrobenzoic acid (DTNB).  
The reaction results in production of 5-thio-2-nitrobenzoate that has yellow color due to 
the shift of electrons to the sulfur atom. 
The animals were sacrificed, whole brains was removed quickly and placed in ice-cold 
saline. The tissues were weighed and homogenized in 0.1M Phosphate buffer (pH 8). 4ml aliquot 
of the homogenate is added to a cuvette containing 2.6ml phosphate buffer (0.1M, pH 8) and 
100µl of DTNB. The contents of the cuvette were mixed thoroughly and absorbance was 
measured at 412nm in a spectrophotometer. When absorbance reaches a stable value, it was 
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recorded as the basal reading. 20µl of substrate i.e., acetylthiocholine was added and change in 
absorbance is recorded. Change in the absorbance per minute was determined. Protein estimation 
was done using folin’s method. AChE activity was calculated using the following formula: 
Calculations 
The enzyme activity is calculated using the following formula 
 
      δO.D ×Volume of Assay (5ml) 
Acetylcholinesterase activity (M/ml) R = 
      E × mg of protein 
Where,     
   rate of en yme activity in  n’ mole of acetylcholine iodide hydroly ed / min/ mg E  
Extinction coefficient13600 M-1cm-1 
δO.D = change in absorbance 
 The final reading of enzyme activity is expressed as μ moles/minute/mg tissue. 
 
(ii)Estimation of Serotonin
73
 
Animals were sacrificed, whole brain was dissected out and the tissues were weighed and 
were homogenized in5ml HCl–butanol for about 1 min. The sample was then centrifuged for 10 
min at 2000 rpm. An aliquot of supernatant phase (1ml) was removed and added to centrifuge 
tube containing 2.5ml heptane and 0.31ml of 0.1MHCl. After 10 min of vigorous shaking, the  
tube  was  centrifuged  under  the  same  conditions  as  above  in  order  to  separate the  two  
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phases and  the  overlaying  organic  phase  was  discarded. The aqueous phase (0.2ml) was then 
taken for serotonin assay. 
To 0.2ml aqueous extract, 0.25ml of OPT reagent was added. The fluorophore was 
developed by heating to 100°C for 10min. After the samples reached equilibrium with the 
ambient temperature, readings were taken at 360-470nm in the spectroflurimeter. 
5.4 STATISTICAL ANALYSIS 
All the values were expressed as mean ±SD. The data was statistically analyzed by one 
way ANOVA. One way analysis of variance (ANOVA) was used to correlate the statistical 
difference between the variables. P< 0.05, P<0.001 was considered to be significant. 
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6. RESULTS 
 
6.1 In vivo methods for memory enhancing activity. 
 
Effect of Desmodium gangeticum root extract ( ethyl acetate & ethanol) and  
piracetam on scopolamine induced amnesia in mice using Morris water maze. (Escape 
Latency Time in Seconds ) 
Table no 3: Treatment effect on Escape latency in 18
th
 day(By Morris Water Maze)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are mean ± SD. (n=6). 
*indicates P< 0.001 compared to control, 
** indicates P<0.001 compared to disease control. 
 
Figure: 11Treatment effect on Escape latency in 18
th
 day (By Morris Water Maze 
 
 
 
15.33 
28.83 
18.5 
20.5 
22.33 
0 
5 
10 
15 
20 
25 
30 
35 
CONTROL DC STD DGEE DGEAE 
E
sc
a
p
e 
la
te
n
cy
 i
n
 s
ec
. 
Group Treatment 
 
Escape latency 
1 Control 
 
15.33±1.2 
2 Scopolamine(0.4mg/kg) 
 
28.83±2.1* 
3 Piracetam(200mg/kg) 
 
18.50±0.95** 
4 DGEE(200mg/kg) 
 
20.50±1.2** 
5 DGEAE(200mg/kg) 
 
22.33±1.8** 
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The memory enhancing effects of Desmodium gangeticum are presented in table 3. It 
was observed that when scopolamine administered, it has significantly (P<0.001) increased 
escape lantency value (28.83±2.1) as compared to the normal group (15.33±1.2). When the 
piracetam was administered for fifteen days at the dose of 200mg/kg, it has significantly 
(P<0.001) decreased escape lantency value (18.50±0.95) as compared to the scopolamine 
treated group. It was observed that administration of Desmodium  gangeticum ethanol & ethyl 
acetate extract at the dose of 200mg/kg resulted in a significant decreased escape latency 
value(for ethanol 20.5±1.2, for ethyl acetate 22.33±1.8 ) as compared to the scopolamine 
treated group. It has shown effect similar to that of piracetam. 
There is an increase in escape latency in negative control group when compared with 
the control group (P<0.001) of the two groups of amnesia induced animals, both showed 
decreased time to escape on to the escape platform. The group treated with ethyl acetate 
extract of DG 200mg/kg & ethanol extract of DG 200 mg/kg showed the decreased escape 
latency and the significance value of (P<0.001) respectively as shown in table 3. 
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Effect of Desmodium gangeticum root extract (ethyl acetate & ethanol) and  piracetam 
on scopolamine induced amnesia in mice using Y- maze.(Percentage alteration) 
Table No: 4 Treatment effect on Percentage alteration in 18
th 
day (By Y- Maze) 
Group Treatment 
 
Percentage alteration 
1 Control 
 
60.82±2.6 
2 Scopolamine(0.4mg/kg) 
 
42.69±3.3* 
3 Piracetam(200mg/kg) 
 
50.39±2.1* 
4 DGEE(200mg/kg) 
 
47.37±6.3** 
5 DGEAE(200mg/kg) 
 
45.43±2.5** 
Values are mean ±SD. (n=6). 
* indicates P< 0.001, 
** indicates P<0.01. 
 
Figure: 12 Treatment effect on Percentage alteration in 18
th 
day (By Y- Maze) 
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It was observed that administration of scopolamine resulted in a significant (P< 0.001) 
decreased percentage alteration value (42.69±3.3) as compared to the normal group 
(60.82±2.6).  Administration of piracetam for fifteen days at the dose of 200mg/kg, has 
resulted in significant increased percentage altertion value (50.39±2.1) as compared to the 
scopolamine group. It was observed that administration of Desmodium gangeticum ethanol & 
ethyl acetate extract at the dose of 200mg/kg resulted in a significant (P< 0.01) increased 
percentage alteration value (for ethanol 47.37±6.3, for ethyl acetate 45.43±2.5) as compared 
to the scopolamine treated group. It has shown effect similar to that of piracetam. 
The amnesia induced group (negative control) indicated decrease in the alternation of 
behaviour. The results presented by the treatment groups was showed significance by 
(P<0.01) increase in alteration of behaviour in respect of 200mg/kg of DGEE and 200mg/kg 
of DGEAE when compared with that of the disease control group. The significance of 
(P<0.001) (P<0.01) respectively as shown in table.4. 
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6.2 Ex vivo methods for memory enhancing activity 
 
Effect of Desmodium gangeticum root extract (ethyl acetate & ethanol) and  piracetam 
on scopolamine induced amnesia in mice using estimation of serotonin activity in  µg/1mg of 
brain tissue. 
Table no: 5 Treatment effect on Serotonin activity in brain tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are mean ±SD (n=6). 
* indicates P< 0.001 compared to control, 
** indicates P<0.001 compared to disease control. 
 
Figure: 13 Treatment effect on Serotonin activity in brain tissue 
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Group Treatment 
 
Serotonin activity 
(µg/1mg of brain tissue) 
1 Control 
 
0.58±0.01 
2 Scopolamine(0.4mg/kg) 
 
0.12±0.01* 
3 Piracetam(200mg/kg) 
 
0.38±0.01** 
4 DGEE(200mg/kg) 
 
0.18±0.01** 
5 DGEAE(200mg/kg) 
 
0.28±0.01** 
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In this study  to determined the level of serotonin in the whole brain homogenate of 
all group animals, which was used to assess the nootropic activity. It was observed that 
administration of Scopolamine resulted in a significantly (P < 0.001) decreased serotonin 
values (0.12±0.01) as compared to the normal group (0.58±0.01). When the Piracetam was 
administered at the dose of 200mg/kg, it has significantly increased serotonin value 
(0.38±0.01) as compared to the Scopolamine treated group. The activity of serotonin after 
administration of Desmodium gangeticum ethanol & ethyl acetate extract at the dose of 
200mg/kg resulted in a significant increased  serotonin  value (for ethanol 0.18±0.01, for 
ethyl acetate 0.28±0.01 ) as compared to the Scopolamine treated group. Piracetam, 
Desmodium gangeticum ethanol and ethyl acetate extract has significant nootropic activity as 
that of Piracetam on scopolamine induced amnesia in mice and also showed synergistic 
effect. 
There is a decrease in serotonin activity in disease control group when compared with 
the control group (P<0.001) of the two groups of amnesia induced animals, both showed 
decreased in serotonin activity. The group treated with 200&200 mg/kg DGEE & DGEAE 
showed increased serotonin activity compared with disease control group. The significance of 
(P<0.001) respectively as shown in table.5. 
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Effect of Desmodium gangeticum root extract (ethyl acetate & ethanol) and  piracetam 
on scopolamine induced amnesia in mice using the estimation of AChE activity in µ mol. 
Table no: 6 Treatment effect on Acetylcholinesterase activity in µ moles 
 
 
 
 
 
 
 
Values are mean ±SD (n=6). 
* indicates P< 0.001 compared to control, 
** indicates P< 0.001 compared to disease control.. 
 
Figure: 14Treatment effect on Acetylcholinesterase activity in µ moles 
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Acetylcholinesterase 
activity (µmoles) 
1 Control 
 
150±3.39 
2 Scopolamine(0.4mg/kg) 
 
218±4.19* 
3 Piracetam(200mg/kg) 
 
128±0.77** 
4 DGEE(200mg/kg) 
 
115±1.12** 
5 DGEAE(200mg/kg) 
 
109±1.15** 
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In this study to determined the level of AChE in the whole brain homogenate of all 
group animals, which was used to assess the nootropic activity. It was observed that 
administration of Scopolamine resulted in a significantly (P < 0.001) increased AChE values 
(218±4.19) as compared to the normal group (150±3.39). When the Piracetam was 
administered at the dose of 200mg/kg, it has significantly decreased AChE value (128±0.77) 
as compared to the Scopolamine treated group. The activity of AChE after administration of 
Desmodium gangeticum ethanol & ethyl acetate extract at the dose of 200mg/kg resulted in a 
significant decreased AChE value (for ethanol 115±1.12, for ethyl acetate 109±1.15) as 
compared to the Scopolamine treated group. Piracetam, Desmodium gangeticum ethanol and 
ethyl acetate extract has significant nootropic activity as that of Piracetam on scopolamine 
induced amnesia in mice and also showed synergistic effect. 
There is an increase in AChE activity in disease control group when compared with 
the control group (P<0.001) of the two groups of amnesia induced animals, both showed 
decreased in AChE activity. The group treated with 200&200 mg/kg DGEE & DGEAE 
showed decreased AChE activity compared with disease control group. The significance of 
(P<0.001) respectively as shown in table.6. 
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                                              7. DISCUSSION 
 Alzheimer’s disease is a genetically heterogeneous neurodegenerative disorder, 
which is slow in onset but relentless in progress. It is characterized by aphasia, apraxia, 
and agnosia with the loss of memory as the mine symptoms. Despite the severity and high 
prevalence of this disease, allopathic system of medicines is yet to provide a satisfactory 
antidote. Therefore we were motivated to explore the potential of medicinal plants to 
manage this deadly disease (AD) 
4
. 
Desmodium gangeticum roots were extracted with various solvents like n-hexane, 
ethyl acetate and ethanol based on its polarity by continuous hot percolation method. The 
ethyl acetate and ethanol solvents given more percentage of yields compare to n- hexane. 
So ethanol and ethyl acetate extracts only chosen for in vivo and ex vivo methods. 
In the present study, D. gangeticum extract administered orally for 18 days 
improved the memory of mice as reflected by diminished escape latency and percentage 
alteration values as compared to control animals. Additionally, D. gangeticum reduced 
central cholinesterase activity, and enhances serotonin activity.  Furthermore, pretreatment 
with D. gangeticum for 15 days protected the animals from memory deficits produced by 
scopolamine. These findings suggested the possible neuroprotective role for D. 
gangeticum. 
There is an increase in escape latency in negative control group when compared 
with the control group (P<0.001) of the two groups of amnesia induced animals, both 
showed decreased time to escape on to the escape platform.  
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The group treated with ethyl acetate extract of D. gangeticum 200mg/kg & ethanol 
extract of D. gangeticum 200 mg/kg showed the significance of (P<0.001) respectively as 
shown in table 3. 
The amnesia induced group (negative control) indicated decrease in the alternation 
of behavior. The results presented by the treatment groups was showed significance by 
(p<0.01) increase inalteration of behavior in respect of 200mg/kg of DGEE and 200mg/kg 
of DGEAE when compared with that of the disease control group. The significance of 
(P<0.001) (P˂0.01) respectively as shown in table.4 
There is a decrease in serotonin activity in disease control group when compared 
with the control group (P<0.001) of the two groups of amnesia induced animals, both 
showed decreased in serotonin activity. The group treated with 200&200 mg/kg DGEE & 
DGEAE showed increased serotonin activity compared with disease control group. The 
significance of (P<0.001) respectively as shown in table.5 
There is an increase in AChE activity in disease control group when compared 
with the control group (P<0.001) of the two groups of amnesia induced animals, both 
showed decreased in AChE activity. The group treated with 200&200 mg/kg DGEE & 
DGEAE showed decreased AChE activity compared with disease control group. The 
significance of (P<0.001) respectively as shown in table.6. 
Nootropic represent a new class of psychotropic agents with selective facilitatory 
effect on integrative functions of the central nervous system, particularly on intellectual 
performances, learning capability and memory. Piracetam, the first representation of a 
class of Nootropic agents, has been shown to improve memory deficits in individuals. 
Repeated injection of piracetam had improved learning abilities and memory capacities of 
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laboratory animals. Both piracetam and D. gangeticum meet major criteria for Nootropic 
activity, improvement of memory in absence of cognitive deficit
20
. 
 Epidemiological studies have almost confirmed that non-steroidal anti-
inflammatory drugs reduce the incidence of Alzheimer’s disease. D. gangeticum has been 
shown to produce anti-inflammatory action in rodents. This anti-inflammatory effect of D. 
gangeticum would certainly help Alzheimer’s disease patients. Oxygen free-radicals are 
implicated in the process of age-related decline in cognitive performance and may be 
responsible for the development of Alzheimer’s disease in elderly persons. 
D. gangeticum has been reported to possess antioxidant property as well. The 
neuroprotective effect of D. gangeticum may attributed to its antioxidant property by 
virtue of which susceptible brain cells get exposed to less oxidative stress resulting in 
reduce brain damage and improved neuronal functions
22
. 
 The symptoms of dementia are presumed to be related to impaired 
neurotransmission and degeneration of neuronal circuits in the affected brain areas. 
Cognitive deterioration occurring in patients with Alzheimer’s disease is associated with 
progressive loss of cholinergic neurons and consequent decline in levels of acetylcholine 
(Ach) in brain
3
. 
 Serotonin deficiency increases the risk for heart disease, dementia and 
Alzheimer’s. Previous research findings using Zingibe roffcinalis, Brahm rasayana and 
Hibiscus sabdariffa have displayed a link between memory improving effect and 
cholinesterase activity. Griffonia’s seeds contain 20% 5-HTP.  
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In the present study, the ethyl acetate,ethanol extract ofD. gangeticum significantly 
decreased the AChE level and enhance the serotonin levels in the mice whole brain 
homogenate, indicting its potential in the attenuation of severity of Alzheimer’s disease. 
 In the present study was showed that ethyl acetate and ethanol extracts of D. 
gangeticum extract exhibited,  
1. Decreased acetylcholinesterase enzyme levels 
2. Enhanced serotonin levels 
3. Ultimately improved memory of mice in both exteroceptive and interoceptive 
behavioral models. 
During the process of learning and memory formation the brain undergoes a 
physical and chemical change which is called as synaptic plasticity. It shows involvement 
of various signal transduction pathways, induction of gene expression which results in 
formation of new synapses between nerve cells. This process undergoes a continuous 
remodeling with time and new experiences. The free radical theory of aging is one of the 
most popular, single mechanistic theories of aging, which discloses increased generation 
of free radical as the major cause of cellular damage. Such free radical-mediated damages 
are prevalent during aging which leads to age associated diseases like Alzheimer’s 
disease (AD) and Parkinson’s disease. Impairment of memory is the initial and most 
significant symptom.  
Alzheimer’s diseaseis associated with a decline in cognitive abilities. The most 
common cause of dementia in the elderly is probably Alzheimer’s disease. Despite the 
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severity and high prevalence of this disease, the allopathic system is yet to provide a 
satisfactory antidote. 
In the present study, D. gangeticum ethyl acetate and ethanol extract (200mg/kg 
and 200mg/kg) administered orally improved learning and memory of mice assessed by 
the behavioral models like Y-Maze, Morris Water Maze and also interoceptive model like 
estimation of acetylcholinesterase and serotonin activity in brain tissue by 
spectroflurimetric method compared to the scopolamine induced mice. (Disease control) 
Thus a combination of anticholinesterase, serotonergic agonist, neuroprotective 
effects exhibited by D. gangeticum may all be eventually responsible for memory 
improving effect was observed in the present study. 
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                                      8. CONCLUSION 
 
 
The central cholinergic system & serotonergic system plays an important role in 
learning and memory. In the present study, Desmodium gangeticum roots extracts 
(200mg/kg of ethyl acetate and 200mg/kg of ethanol) administered orally improved 
learning and memory of mice assessed by the behavioral models like Morris water maze, 
Y-maze. In Scopolamine induced amnesia there is loss of memory.  
The D.gangeticum ethanol extract & D. gangeticum ethyl acetate extract contains 
majorly flavonoids, alkaloids, pterocarpenoids and antioxidant property which may 
responsible for the anti-amnesic effect. 
 The neurotransmitter (acetylcholinesterase and serotonin) estimation of 
ethyl acetate and ethanol root extracts of Desmodium gangeticum by ex 
vivo method was evaluated. 
 The memory activity of ethyl acetate and ethanol root extracts of 
Desmodium gangeticum by in vivo (Morris water maze and Y maze) 
method was evaluated 
Further studies can be carried out in the future to elucidate  the other 
neurotransmitter are to evaluate and then mechanism of action, clinical studies may for 
carried out to establish its efficacy in humans. 
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